- NewsCategory：
- All Company news Industry news
common105One result
-
1031
Gotham Therapeutics Estaσ≤©blishes Advanced Oncology Profiling Casβδcade with ProQinase to Progress its Portfoliλ₩o of Epitranscriptomic ∑↔Drug Candidates
Gotham Therapeutics Es§☆∏∞tablishes Advanced Oncology Profil≥"€ing Cascade with ProQinase to Progressβ£ its Portfolio of Epitranscriptomic → ×Drug CandidatesWEDNESDAY,≠®σ OCTOBER 30, 2019Gotham The$✘rapeutics, a biotechn$εology company developing a novel drug class↑¥ targeting RNA-modifying proteins, and ProQ<÷inase, an early stage d₹™rug-discovery company, recently acquir₽✔αed by Malvern/PA-based Reaction >∑Biology Corp., today anno©¥unced that they have establisheγ≈d an array of advanced biochemical and cellular aΩ₽ssays to characterize •¶φ♠epitranscriptomic-directed compo₹¥βαunds.“Establishing tailored target eng✘<¥↓agement, cell biology, phenotypic, and in-vivo aδ"×ssays to evaluate compounds o±Ωriginating from our three most advanced epitr↑§¥anscriptomic programs in ↕↕≥parallel is a crucial next step to deπ$ velop our broad pipeline towards the clinic,”₩γ said Dr. Gerhard Müller, Chief Scientifβ§ic Officer of Gotham Therapeut€↔ics. “By pursuing th✔♦e full range of the reader-writ∑♦er-eraser continuum, we are able to focus £±on targets with the most compell ¥ing links to disease and advance those progr≈βams in tandem.”“Combining our hi←♦εαgh proficiency in providi&≠πng customized solutions as ≥£₩πearly stage drug-discovery services,£ including tailor-made bioche↓♣♥mical and cell-based assays, ©₹¥with Gotham’s expertise in ← ™epitranscriptomics, we were able to esta ↕✘<blish in a very short time a set of customized en₩®zymatic and cellular assays for co♠π≥mpounds addressing three different mRNA-modifyi≠®ng targets,” said Dr. Sebastian D>π₽πempe, Chief Executive Officer of ™∞↔ProQinase. “We look forward to α supporting Gotham as the company advances its p≈÷rograms into lead optimiza¶ Ωtion and to continued work with th₽φe Gotham team assistin×®™g the company to advance its broad pipelφ±©ine in a time-effective manner.”In a§φ±ddition to establishingα©← a tailor-made profiling cascade for compounds f↔εrom its three most advanced $&₹programs, Gotham has also" made progress in streng♥©✘thening its drug discovery↓♦< engine and developing its candi£λαdate base. Gotham previou™★sly completed the gene-to-lead phase for it£±>↑s drug discovery projecα₹t targeting the METTL3/METTL14 compl→ ex and established a robust discovery process •™≈as a platform for futu←re projects. The company has also generatedε a library of high-quality compounds tailor-made↔& for accelerated hit generation and $±₹πhit-to-lead expansion a×ε♠↔gainst large parts of the ep♠λ itranscriptomic target space. This≥>δ library includes a c≈ ∏•ollection of over 2,000 analogues covering¶"<₹ over 80 distinct ch$λemotypes that will be used to furth" >er accelerate Gotham’s drug d→€iscovery efforts as it expands≈∑ its pipeline.The original link:ht§♣λ✘tps://www.pharmafocusasia.com/news/got§ ♠•ham-therapeutics-establishes-advanced✘↑★-oncology-profiling-cascade-with÷₽♣α-proqinase-to-progress-its-portfolαγ×✘io-of-epitranscriptomic-drug-candidates2019 Asi✘ a-pacific pharma IP Leader S ✘₽ ummit: http://en.zenseegrouΩ£×™p.com/p/510934/will ↕₹♥be held in Beijing &nb≈<§≤sp;on November 14-1®©§5, and will attract more ♣ than 500 industry ex♠↕γperts from domestic and foreign ph∞εarmaceutical companies, biotechnolog£φy companies, governments, a"★ssociations, law firms, intellectu₹ al property agents and o> ther companies to attend.Offi®∞cial registration and consultation channels:≠'Contact：AnnPhone: 021-δα65650305Email：Marketing@zenγ♠∏seegroup.comhttp://en.zenseegroup.com/p/510934 -
1030
Gilead and Glympse Bio Annou©©™βnce Strategic Collaboration for Use of γ™εBiomarker Technology in NASH Clinical D•>×evelopment
Gilead and Glympse Bio Announce Strategic λεCollaboration for Use £↔of Biomarker Technology in NASH Clin×♠∑ical DevelopmentTUESDAY, O♠>CTOBER 29, 2019Gilead Science×αs Inc. and Glympse Bio, Inc., to₽€>♥day announced that thδα≠"e companies have entered into a strategic col™<≈laboration in nonalcoholic steatohepatitis β÷¶'(NASH) clinical developmen∑∞≤∑t. Glympse Bio’s proprie×ε>>tary synthetic biomarkers – bioengineered to ide±<$$ntify stage and progression of disease as well Ω♣✘γas early detection of treatment response –☆≥ will be used to determine clinicalβ trial participants’ stage ≥≠±of disease at initial screening and →♣to determine responseπ±s to study treatment in 'γGilead’s NASH clinical program.“We≤£ are excited about the oppoσπ≈↑rtunity to partner with Glympse Bio to > help inform our NASH development program,” ↔★∞said Mani Subramanian, MD, PhD Senior Vice Preδ•★★sident, Liver Diseases, Gilead Science$φε÷s. “By utilizing this innovative technology$β✘≤, we hope to better characterize this complex di↓→>sease and improve our understandingδπ of how our compounds impac↓♠≠¶t disease progression.”Gl↑ε•ympse Bio’s proprietary techn$✘≈ology, Glympse Inside™, combines synthe§₽≥γtic biomarkers with maαβ★chine learning approaches to ¶§® identify the stage and monitor↔★ progression of important, complex dis↕♠eases such as cancer, fibrosis, inflammat←$ion, and infections, in real time.“We are ₹↓very excited about partnering with Gilead, a l≈★eader in drug development, to help drive eε✔arlier and more favorable ou✘≥<tcomes for patients,” sai♠♣d Caroline J Loew, President and CEO, Glympse∏Ωπ₽ Bio. “Gilead’s commi ≈tment to developing inn§§£∑ovative medicines in areas oσ✔>☆f high unmet medical need aligns with o₽$εur mission of transforming disease detectio↕<£n and measuring treatment resp→'<onse, all with the goal of helping i×ε∞γmprove the lives of patients.”informati§•≥♣on source:pharma focus AsiaThe origin₽'☆al link:https:https:https://www.pharmafocusasia'±.com/news/gilead-and-glympse-bio-aγ≈nnounce-strategic-collaboration-fo→¥✔γr-use-of-biomarker-technology-in-na♥sh-clinical-development2019 Asia£☆-pacific pharma IP Leader Summit:http://en.zen•∏seegroup.com/p/510934/ will ↑♠✔be held in Beijing &n♦←>bsp;on November 14-15<", and will attract more thaλ$λn 500 industry experts from domes®×↔tic and foreign pharmaceutical companie• ☆s, biotechnology companies, g♦overnments, associations, law firms,σ€≠≈ intellectual property age↓ δnts and other companies to↔ attend.Official registration and consultation ch₩annels:Contact：AnnPhone: 021-65650÷≤≈→305Email：Marketing@zenseeg€λ↔βroup.comhttp://en.zenseeδ≤group.com/p/510934 -
1029
HistoIndex Announces Global P∑♣φ✘artnerships To Expand AI-Based Digital P₽ ≤athology Platform
HistoIndex Announces Global Partnerships ε≤©To Expand AI-Based Digital Paαthology PlatformMONDAY, OCTOBER 28, 2019α♦≈∏HistoIndex announcesλ☆ the expansion of its AI-ba×★sed digital patholog↑π•y platform towards large-scale NASH precliniσ∏♥cal programs for pharmaceutical and biotech ↔×±companies to achieve q>™↕uantifiable and reproducibl₩©₽☆e data on therapeutic responses i×n NASH animal models, and to aid CROs as well→ as research agencies in validati≤≤×™ng new models mimickin&↕g the NASH disease.Publis<£•hed preclinical studies h>€ εave demonstrated the use of HistoIndex's fuβεlly quantifiable Second Harmonic Generation (S∞HG) technology as a highly accurate'"•♣ stain-free method that can monδ←itor the efficacy of™φα various therapeutic agents, by quantifying mo✘©re than 450 NASH-assoc÷πiated parameters in fibrosis, inflammation, ballo≈↕÷oning and steatosis. The information of the∞<≤φse NASH-associated parameters gath™Ω₩ered from the entire liver tissue, provides ±$→ comprehensive insights on the mechanis≥πα♦m of action of the therapeutic agent. As a •"¶drug discovery tool, H↔☆±istoIndex's SHG-enab♦©led digital pathology platfo♥εεrm will allow pharmac§ £eutical and biotech companies to select Ωγ☆♦promising lead candi<>↓dates for further optimization a>← nd make informed decisi≥ ₹€ons in the management of their NASH∏∞> drug development pipeline.In addition to ongoin•>σg NASH clinical trials, HistoIndex is curre☆π≥ntly involved in multiple preclinical studies, mo♦≠♣st of which are condu☆₽γcted by major pharmaceut∏₽→<ical and biotech companies, medical universities, ≈§ CROs and research agencies. No©←β✔tably, HistoIndex has recently enteredδ↑↕ into a collaboration with the ✘© A*STAR's Genome Institute of Singapore (GIS) to≠γ↓ validate their in vivo ε®and in vitro NASH models based on Asian-c±ππ>entric clinical data. Says Professor Pat₹→rick Tan, Executive Director of th✔ •<e Genome Institute of Singapor©≠÷e (GIS), "At GIS, we conduct our preclinical stud≤π'ies on fatty liver involving data from animal modε≠ ↑els based on patient-derived ♦©•transcriptomic data. This has a high transl←&' ational potential as it help€<™s us to pinpoint new therapeu€≠ tic targets and their validation. There★&γfore, using a fully q≥✘£Ωuantitative, reliable and objective 'φpathological evaluation such as Hist≈÷₩λoIndex's AI-based digital p÷>Ω±athology platform is δ₽essential to the sucφλcess of our efforts in the"≥rapeutic target discovery."HistoIndex is also aε↓✘ partner with globally-renowned CRO, WuXi Appεβσ tec, in advancing their NASH preclinical program♥≥s with advanced R&D and smart imagin≤≠g analysis capabilities. Published study ±≥≥data will be available for discussions during net∏εworking opportunities throughout A₩✔≈€ASLD's The Liver Meeting® ₩♥ in November 2019. "We are↕ ←€ very excited to extend our AI-based SHG pla≥tform to preclinical studies t>∏o help companies with drug d®★iscovery programs select promising lead candidate&s for further optimization and subsequent c£×↔linical development," says Dr Poon Thong Yu $en, Chief Executive Officer oγ€☆f HistoIndex. "Our SHG image analysis p≈♥latform has already been used to analyσ★>☆ze the efficacy of a series of pr' omising drug candidates for NASH within variousβ☆λ animal models commonly-us§≤± ed by the industry, andδ we believe these preclinical partnershi★•ps will help drive the adoption of o≈$ur platform significantl∞≥↑y."information source:pharma focus AsiaT♦§®he original link:https:https://★σ≥αwww.pharmafocusasia.com/news/histoindex-anδ'nounces-global-partnerships-to-expand-ai-←'↔based-digital-pathology-platfor∞®πm2019 Asia-pacific pharma IP Leader Sum✘₽ε mit: http://en.zenseegroup.com/p/510934/≤↔"will be held in Beijin§£$εg on November 14-15, and ≠≈will attract more than 500 ∏↓♥industry experts from domestic an≠σ✘d foreign pharmaceutical compa≠">nies, biotechnology companies₩δ, governments, assoc≥÷βiations, law firms, intellectu↓•↑al property agents and other↓÷σ companies to attend.Of ≈ficial registration and con✔sultation channels:Contact：A"÷®≥nnPhone: 021-65650305Ema©™≈il：Marketing@zenseegroup.comhttp://en.zens↔σ↓eegroup.com/p/510934 -
1028
AVROBIO Receives Orphan-Drug Designation from↔★' the U.S. FDA for AVR‑RD‑02 for the Treatme≈✘δ™nt of Gaucher Disease
AVROBIO Receives Orphan-Drug Designation fr©€♣®om the U.S. FDA for AVR‑π≠RD‑02 for the Treatme&δ÷♥nt of Gaucher DiseaseFRIDAY, OCTOBER ←®∏25, 2019AVROBIO, Inc., today announc↔←ed that the U.S. Food and Drug Administrati↕ >on (FDA) has granted orphan-drug design α★₽ation for the Company’s invest≥©Ω$igational gene therapy, AVR-RD♠★€-02, for the treatment of Gau☆≤§&cher disease. AVR-RD-02 consiπ±sts of the patient’s own hematopoietic st™≠em cells, genetically modified to express glucoce ₹δεrebrosidase (GCase), ∞ ≈the enzyme that is defγ icient in Gaucher disease. The Company i↔✔s actively recruiting in Canada for its®δ Phase 1/2 clinical trial of AVR-RD☆÷©♦-02, which seeks to evaluate the safet₩←✔≥y and efficacy of the t•™herapy in patients with Type₹↔<' 1 Gaucher disease.“Under the existing standard o♦™$f care, patients with≠® Gaucher disease are bound to a lifelong ÷✘λinfusion schedule of enzyme replacement thera÷∑↑pies, and still experience painful and progr₽✔β∞essive symptoms such as debilitating musculoskelγ£→etal pain and fatigue,” said Birgitte Volck, MDγ±♥, PhD, President of Research a♥↕∞nd Development at AVROBIO. “Or≠¶✘↔phan-drug designation recognαizes the unmet need of populations with rare ₩ diseases like Gaucher where AVROBIO ∑¥∑strives to transform lives by address≈πing the underlying cause o÷π≠©f the disease with a single dose o'÷δ☆f gene therapy.”Orphan-drug designation ✘↕©×is granted by the FDA to drugs and biol©₩ogics which are intended for the saf₩↓e and effective treatment,€♥ε diagnosis or prevention of rare diseases or£↕♠σ conditions that affect fewer than 20→π☆♣0,000 people in the United States. Orphan-↓&×drug designation provides certain incent≠§÷•ives, which may include tax credits towar ±₽σds the cost of clinical trials and prescriptio∞©n drug user fee waivers.information ♠€§♠;source:pharma focus AsiaThe original link:htt↓<≤ps:https://www.pharmafocπ£γusasia.com/news/avrobio-receives-orphanγ↓≈↑-drug-designation-from-the-us-↓✔δ₹fda-for-avrrd02-for-the-tγβ₹✔reatment-of-gaucher-dβ↔γisease2019 Asia-pacific pharma IP Leader Sum≠±↔∞mit: http://en.zenseegroup.com'↔¶/p/510934/will be held ✘←"in Beijing on No↔vember 14-15, and will at$↔tract more than 500 industry experts from d∑δ↑<omestic and foreign pharmaceutical companies, bio♦Ω≤technology companies, go™®≤¥vernments, associations, lawπ↑₹ firms, intellectual property agen♥™ts and other companies to attend.Offi<≥cial registration and consultπ§✔ation channels:Contact：AnnPhone: 021-65650↑±↓ 305Email：Marketing@zenseegroup.comhttp:>'★//en.zenseegroup.com/p/510934 -
1026
AZTherapies Strengthens Neuroinflammation- π✔↓Targeted Pipeline Through Acquisλition of Smith Therapeutics
FRIDAY, OCTOBER 25, 2019AZTherapi×÷∞Ωes, Inc., a biopharmaceutical ¥ββcompany developing therapeutics to extend bra→♦>×in health, today announce×∑d the acquisition of Smith Therap↕®eutics, a private biopharmaceutical company w≠÷÷≈ith a shared goal of targeting neuroinflammat ✔ion to treat neurodegenerative dis∏✘ease. Smith Therapeutics’ Founder and Chie>§f Executive Officer Philip As ↔£φhton-Rickardt, Ph.D., h"Ω≥•as joined the senior leadership team at AZT&₩herapies as Senior Vice President of Immuno Ω♠↓logy. Financial terms of the acq¶♥♥≠uisition were not disclosed.Smith Th ∞λerapeutics’ proprietary research platform focusσ®↑₹es on the use of modifie¥↕&©d T cells to restore •∏a healthy balance of inflammatory and regulatoryσ₹ cells in the brain. To dateΩ ✔™, Smith has successfully en<♣gineered immunosuppressive©α≠ T regulatory (Treg) cells with Chimericφβ Antigen Receptors (CAβλRs) targeting brain glδ$♥✘ial cells. Previous research has demonstrated t₩→he ability of Tregs to dampen microglial acti★ε★vity and reduce neuroinflammat₩"ion in models of neurodegeneration, suggesting™≠® their potential utility in♦∞ the treatment of diseases i®'™♠ncluding Progressive Supranucle≤§₹∑ar Palsy (PSP), Alzheimer’s disease, Parkinson’s≠φ disease, Huntington’s disease, Amy÷∑σβotrophic Lateral Sclerosis (ALS), and others.“Thiγ s acquisition represents a meaningfσΩ↑ul step forward for us as we continue to strβ©↑engthen our leadership position in the devλσ✘♥elopment of therapies targeting neuroinflamma<≠tion to stop or slow the progression of neurode↓↑generative diseases,” said David R. E↑₽γlmaleh, Ph.D., Founder, CEO, and Chaiλ€☆₽rman of AZTherapies. “We are excited to b↓≈e working with Philip as we add this ¶cutting-edge technology to our portfolio of i↑♦nnovative programs. An esteemed immunolΩ✔σ$ogist and inventor of the t₩♦echnology, Philip brings ¶•unparalleled expertise to the company and we look≤↑♣∞ forward to advancing this CAR-Treg program fu¶✔ rther into IND-enabling studies and into$↔♥ clinical development as rapidly as possibl♣≠♦e.”Dr. Ashton-Rickardt commented on the acα•≠'quisition and his appointment: “Our shaγ★red rationale of targeting neur₩ oinflammation as the root cause of neur™'odegenerative disease m≥♦akes this acquisition a great strategic Ω♠fit for us. With AZTherapies’ expertis ↓$e in drug development and clinical trial ® execution, we believe that together, we are≠÷ well positioned to advance our♣π€ CAR-Treg technology ₽€and fundamentally change neurodegener✔£δative disease progression.<<→§”Prior to launching ∞"Smith Therapeutics in 2017, Dr. Ashton-♣¶Rickardt was Chair in Immunology at Imperial ↓→✘✔College London, Visitin✔σg Professor, Brigham and Women’s Hospital, H ©← arvard Medical School, and Associ±>ate Professor in the Depar₽Ω€ tment of Pathology at the University of Ch↕δ↔φicago. His work has been≈φ recognized by his peers through the award≠✔ of tenure from The Un¶ π$iversity of Chicago and by his fellow citize♠<→ns as a recipient of the Early☆♠>€ Career Award for Scientists and Engineers ↕®from President Bill Clinto™§♥n. He has published more than 65 peer-re←ε≠•viewed papers in more than 30 academic journa♠¥↑ls (including Cell, Scienc<₹e, Immunity, and Nature Imm↔™¥"unology), has served as an ×≈editor for several academic journals, and has beeλε✔≤n a member of grant rφ↑eview boards globally. Dr. Ashton-Rickardt rec¶∞×≈eived a B.Sc. in Biochemis←₽™γtry from the University of ΩLondon, King’s College with honors, a Phπ☆±↑.D. in Molecular Biology≈ from the University 'σ∏™of Edinburgh, and complete≤€εd post-doctoral work atφσα the University of E β≈dinburgh and the Massachusetts Institute of TecΩ>hnology in Molecular Biology and Molecular Immu δnology, respectively.information source:p ×harma focus AsiaThe original linkλφ♦≤:https:https://www.pharmafocusasia.com/news/az≤≤∞therapies-strengthens-neuroinflammation-targeted•☆-pipeline-through-acqui ÷≥✔sition-of-smith-therapeutics2019 As≥Ω•ia-pacific pharma IP Leader ✘'±Summit: http://en.zenseegroup.c¥☆ om/p/510934/will be held in&nbsφβ₩>p;Beijing on €σ>$;November 14-15, and will attract moreλε★∑ than 500 industry experts from § βdomestic and foreign pharmaceutical↑≠✔∞ companies, biotechnology companies, gove&♠∞≤rnments, associations, law firms, intel÷×↕λlectual property agents and other c™♣♠ompanies to attend.Official registration and co↓≠nsultation channels:Contact：AnnPhone: 021-65®★ ≈650305Email：Marketing@z×₽enseegroup.comhttp://en.zenseegroup.com/p/51ε™ $0934
Contact Us
Zensee_Daystar online
© 2011-2016